Compare NextEra Energy, Inc. (NEE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? NextEra Energy, Inc. trades at $78.58 (market cap $163.17B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: NextEra Energy, Inc. is far larger — about 33.4× Travere Therapeutics Inc. Common Stock's market cap, and NextEra Energy, Inc. pays a 3.19% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NEE | TVTX | |
|---|---|---|
Market Cap | $163.17B | $4.88B |
Volume | 9,492,162 | 1,668,577 |
Sector | Utilities | Health |
52-Week High | $97.88 | $67.52 |
52-Week Low | $75.49 | $26.79 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $270.50B | $5.01B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $78.37, down 0.18% today, with a bullish technical signal but mixed indicators. The company reported strong earnings beats in Q1 and Q2 2026, with revenue growth and a net income margin of 32.4%. Recent news highlights expansion in gas generation and a major infrastructure partnership. Analyst consensus is strongly bullish with a $96 price target, though the stock is near a 52-week low of $74.78, indicating potential value.
Outlook is positive due to robust fundamentals and growth initiatives, but risks include rising debt levels and interest rate sensitivity. The stock offers a dividend yield with upcoming payment, supporting income investors. Upside potential exists if earnings momentum continues, but macroeconomic headwinds and competitive pressures warrant caution.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
